A Multicentre, Randomised, Open-labelled, Parallel-group, Activecontrolled Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
Phase of Trial: Phase III
Latest Information Update: 22 Oct 2018
At a glance
- Drugs Somapacitan (Primary) ; Somatrogon
- Indications Somatotropin deficiency
- Focus Adverse reactions; Registrational
- Sponsors Novo Nordisk
- 12 Oct 2018 Status changed from active, no longer recruiting to completed.
- 04 Oct 2018 Planned primary completion date changed from 28 Sep 2018 to 4 Oct 2018.
- 05 Oct 2017 Status changed from recruiting to active, no longer recruiting.